Loading...
•
Sep 30
GE HealthCare Q3 2025 Earnings Report
GE HealthCare delivered solid Q3 2025 results, with 6% revenue growth and higher adjusted EPS, supported by strong performance in Imaging and PDx.
Key Takeaways
GE HealthCare posted a strong third quarter, driven by 6% organic revenue growth, improved adjusted EBIT margin, and continued strategic investments in innovation and productivity.
Revenue reached $5.14B, up 6% organically year-over-year.
GAAP EPS was $0.98; Adjusted EPS was $1.07, up 4% year-over-year.
Imaging and Pharmaceutical Diagnostics drove performance, each growing 9%.
Raised the lower end of full-year adjusted EPS guidance to $4.25–$4.35.
GE HealthCare
GE HealthCare
GE HealthCare Revenue by Segment
GE HealthCare Revenue by Geographic Location
Revenue by Segment
Imaging Revenue
CapyFin.comPatient Care Solutions (PCS) Revenue
CapyFin.comPharmaceutical Diagnostics (PDx) Revenue
CapyFin.comOther Revenue
CapyFin.comRevenue by Geographic Location
United States Revenue
CapyFin.com Forward Guidance
GE HealthCare raised the lower end of its full-year adjusted EPS outlook to $4.25–$4.35 and reaffirmed revenue and margin expectations.
Positive Outlook
- Increased lower end of adjusted EPS guidance to $4.25.
- Reaffirmed 4–6% organic revenue growth outlook for FY25.
- Reaffirmed adjusted EBIT margin guidance of 15.3–15.7%.
- Strength in Imaging and PDx continues into Q4.
- Ongoing productivity and price realization expected to support margins.
Challenges Ahead
- PCS revenue slightly declined YoY in the quarter.
- Continued FX headwinds expected into Q4.
- Productivity gains partially offset by inflationary pressure.
- Modest growth expected in Europe and Latin America.
- China remains a soft spot with limited near-term rebound.